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Abstract.
Background: Empirical models of the natural history of Alzheimer’s disease (AD) may help to evaluate new interventions for
AD.
Objective: We aimed to estimate AD-free survival time in people with mild cognitive impairment (MCI) and decline of cognitive
and physical function in AD cases.
Methods: Within the Kungsholmen project, 153 incident MCI and 323 incident AD cases (international criteria) were identified
during 9 years of follow-up in a cognitively healthy cohort of elderly people aged ≥75 at baseline (n = 1,082). Global cognitive
function was assessed with the Mini-Mental State Examination (MMSE), and daily life function was evaluated with the Katz
index of activities of daily living (ADL) at each follow-up examination. Data were analyzed using parametric survival analysis
and mixed effect models.
Results: Median AD-free survival time of 153 participants with incident MCI was 3.5 years. Among 323 incident AD cases, the
cognitive decline was 1.84 MMSE points per year, which was significantly associated with age. Physical functioning declined
by 0.38 ADL points per year and was significantly associated with age, education, and MMSE, but not with gender.
Conclusion: Elderly people with MCI may develop AD in approximately 3.5 years. Both cognitive and physical function
may decline gradually after AD onset. The empirical models can be used to evaluate long-term disease progression of new
interventions for AD.
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INTRODUCTION
Alzheimer’s disease (AD), the most common cause
of dementia, is characterized by a gradual onset and
a decline of cognition and functional ability to the
stages of complete dependence on informal or for-
mal care. When studying the disease, it is therefore
important to adopt a long time horizon to capture all
disease-related events. Disease modifying treatments
are being developed to reduce individual and soci-
etal burden, but randomized trials to evaluate such
interventions require many years of follow-up to cap-
ture their long-term consequences, whereas most trials
have employed a short follow-up period [1]. Long-
term follow-up requires large investments of resources,
and if new interventions emerge during the follow-up
period, ethical concerns arise regarding withholding
possibly successful treatment for a prolonged period.
As an alternative, empirical models can be used to
predict long-term consequences by integrating trial
outcomes with estimations of natural disease progres-
sion [2, 3]. In addition, empirical models are a crucial
component of economic decision models [4] that gen-
erate evidence for care policy making.
Natural progression models in AD have been devel-
oped in several studies [5], mostly among clinical
samples or prevalent AD dementia cases. However,
disease modifying treatments are supposed to be effec-
tive in early (pre-dementia) AD, thus long-term data
on the natural course are required to evaluate their
effectiveness. Such target populations have not been
reflected by previous studies, leaving an urgent need
for population-based empirical models that describe
the long-term natural progression of the dementia and
pre-dementia phases of AD. In the present study, we
aimed to build empirical models that estimate (1) the
time from incident mild cognitive impairment (MCI)
to AD-type dementia and (2) the changes of cognition
and function in incident AD dementia cased from a
population-based cohort.
METHODS
Study sample
The study sample was derived from the Kungshol-
men Project, a population-based cohort study on aging
and dementia, which has been fully described else-
where [6, 7]. Briefly, all registered inhabitants of the
Kungsholmen district of Stockholm, Sweden, who
were aged ≥75 years in October 1987, were initially
invited to participate in the project. At baseline, 225 of
the 1,810 participants were diagnosed with dementia
according to the criteria of the Diagnostic and Statisti-
cal Manual of Mental Disorders, Revised Third Edition
(DSM-III-R) [8], based on a 2-phase survey, and 110
participants refused the extensive evaluations. Of the
remaining 1,475 dementia-free persons, 355 with MCI
(130 with amnestic MCI (aMCI) and 225 with other
cognitive impairment not demented (OCIND)) at base-
line and 38 with very low global cognitive status in the
absence of a dementia diagnosis (Mini-Mental State
Examination (MMSE) [9]<20) were excluded, leaving
1,082 cognitively healthy subjects at baseline.
The participants of the present study were persons
with incident MCI and AD-type dementia (either AD
or mixed AD & vascular dementia). A 6-year instead
of 9-year follow-up for incident MCI was applied to
preserve a 3-year exposure term (from 6–9 years) for
the progression of MCI to AD dementia as explained
below.
During the 9-year follow-up, three sets of clinical
examinations were carried out, with average inter-
vals of 3 years. Informed consent was obtained for
all participants, with informants providing consent for
cognitively impaired persons. The ethics committee
at the Karolinska Institutet, Stockholm, approved all
phases of the Kungsholmen Project.
Data collection
Data on demographic features (i.e., age, gender, and
education) was collected at baseline using standardized
protocols [6, 7].
Global cognitive functioning was assessed with the
MMSE, and dependency was assessed using the Katz
index of activities of daily living (ADL) [10] with
scores ranging from 0 (not dependent for ADL) to 6
(fully dependent for ADL).
Diagnosis of dementia
During the follow-up period, a diagnosis of dementia
(including both questionable and definite diagnoses)
was established by the examining physicians, based
on a comprehensive clinical examination and cogni-
tive tests according to the DSM-III-R criteria [11]. The
diagnostic criteria applied were equivalent to prob-
able AD according to the criteria of the National
Institute of Neurological and Communicative Dis-
orders and Stroke-Alzheimer’s Disease and Related
Disorders Association [12], and according to those of
the National Institute of Neurological Disorders and
Stroke-Association Internationale pour la Recherche
et l’Enseignement en Neurosciences [13].
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Definition of MCI
aMCI was defined according to the original Mayo
clinic criteria, and operationalized according to pre-
vious research [14, 15], as follows: (1) presence of
a memory complaint reported by the participant or
by a close informant during the nurse interview; (2)
preserved general cognitive functioning, defined as
scoring above the minus 1 SD cut-off on age and educa-
tion adjusted MMSE means; (3) absence of dementia,
verified by clinical examination; (4) preserved func-
tional independence defined as no impairment on the
Katz ADL scale; (5) presence of objective memory
impairment defined as scoring ≥1.5 SD below age-
and education-specific means on a verbal memory task
of free recall of slowly and rapidly presented words
[16]. All cases with global cognitive impairment that
did not fulfill criteria for dementia were classified
as OCIND and operationalized according to previous
research [17] as follows: (1) impaired general cognitive
function, defined as scoring 1 SD or more below age
and education adjusted means on the MMSE derived
from the dementia free population at baseline; and
(2) absence of dementia, verified by clinical exami-
nation. aMCI and OCIND were mutually exclusive in
the present study, therefore a broader category of MCI
was created which included cases classified as aMCI
or OCIND. The analyses were based on the incident
cases of AD detected at the 3-, 6-, or 9-year follow-up
measurements and incident cases of MCI detected at
the 3- or 6-year follow-up measurement.
Statistical analysis
Survival analysis was applied to estimate the time
from incident MCI to AD-type dementia. The effect of
age at diagnosis of MCI, gender, education, MMSE,
and ADL at diagnosis, and all 2-way interactions was
assessed. A stepwise procedure was used (removing
interactions with highest p-values first until p < 0.05,
followed by the predictors).
A mixed model with random subject effects was
applied to determine the decline in cognition and ADL
over time in incident AD participants. A stepwise pro-
cedure was used and predictors were included if the
goodness-of-fit statistics −2 log likelihood change and
Wald z of the predictor were significant. The follow-
ing steps were used to determine the final MMSE
prediction model: (1) include time, as years after
being diagnosed with AD; (2) include a random inter-
cept; (3) determine if time is non-linear by stepwise
adding a higher-order polynomial of time (time2,
Table 1
Characteristics of the participants with incident MCI and AD
dementia
Characteristics Incident MCI Incident AD
(n = 153) (n = 323)
Age in years; mean (SD) 83.4 (4.0) 86.7 (4.1)
Female; % 75% 83%
Years of education; mean (SD) 8.5 (3.0) 8.2 (2.9)
MMSE score; mean (SD) 24.4 (2.1) 19.7 (5.0)
Katz ADL score; mean (SD) 0.4 (0.7) 1.2 (1.7)
time2 + time2+n, etc.); (4) include a random time fac-
tor; (5) include gender, age, and education and all
2-way interactions and remove interactions with high-
est p-values first until p < 0.05, followed by predictors.
A similar procedure was used to analyze decline in
ADL, and the effect of MMSE was also determined.
The onset of MCI as well as that of AD was assumed
to have taken place in the middle of each follow-up
interval (each lasting an average of 3 years). This was
operationalized by adding a time correction of 1.5 years
to all diagnoses. Survival analysis was performed using
Stata-12, mixed effect models using SPSS-20.
RESULTS
Out of 1,082 cognitively healthy participants at base-
line, 153 developed MCI (40 aMCI and 113 OCIND)
and 323 developed AD during the 6 and 9 years of
follow-up, respectively. The mean age at diagnosis of
MCI was 83 years, while the mean age at AD diagnosis
was 87 years (Table 1). Figure 1 provides an overview
of the observed MMSE scores over time in the pre-
dementia phase (captured by the survival analysis) and
dementia phase (captured by the regression model).
AD-free survival
Among the 153 participants with incident MCI, 48
(31%) developed AD dementia, after a median time of
3.03 years (658 person-years). The incidence rate was
0.073 (95% CI: 0.055 to 0.097). Twenty-nine percent
of the participants died during follow-up.
Univariate analysis only showed a significant effect
of gender. In the multivariate stepwise analyses,
women had a significantly shorter time from MCI to
AD than the men (4.2 and 4.6 years, respectively; haz-
ard ratio = 0.38) and none of the 2 way interactions
were significant (Table 2). The observed times until
90% and 75% of the MCI cohort were still AD-free
were 2.9 and 3.2 years, respectively. The 50% AD-free
survival was not reached within the 6-year observation
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period. Using the fitted model, the estimated times until
90%, 75%, and 50% of the MCI cohort had survived
without developing AD dementia were 2.8, 4.6, and
7.1 years, respectively (see Box 1).
BOX 1
The survivor function is described by equation (1),
where S(t) is the proportion of AD-free survival, t
is time in years, a is the exponent of the survival
analysis coefficient estimates, and p is the Weibull
shape parameter. This function can be rewritten to
estimate the time until a specific proportion (S) of an
MCI cohort has progressed to AD dementia, where
gender 0 = female and gender 1 = male (equation 2).
S(t) = e−atp (1)
t = p
√
1n(S)
−a (2)
t = 2.01
√
1n(S)
−e−4.06−0.96 genderi (3)
The course of the MMSE can be summarized by
regression formula (4) and the course of ADL by
regression formula (5), where r is a random number
from a normal distribution to reflect the variance in
the random effects, and i is the individual participant.
MMSEi = (26.87 ±
√
2.0ri) − (3.26
±
√
1.86ri)timei − 0.35(agei − 75)
+ 0.10 timei (agei − 75) + ei (4)
Katz indexi =
(
−0.82 ±
√
0.71ri
)
+ 0.26 timei + 0.26 (agei − 75)
+ 0.06 education − 0.02MMSE
− 0.01MMSEi(agei − 75)
− 0.01MMSEitimei = ei (5)
Decline in cognitive and physical function
For the 323 participants who developed AD dur-
ing follow-up, 313 MMSE scores were available at the
moment of AD diagnosis, 109 at 3 years after diagno-
sis, and 28 at 6 years after diagnosis. Forty-nine percent
of the participants died during the follow-up.
Figure 2a presents the observed average MMSE
scores over time, with 0 representing the moment of
AD diagnosis. The univariate analyses showed that
age and time (as years after being diagnosed with
AD) significantly predicted the MMSE score, with an
average rate of decline of −1.84 MMSE points per
year. The multivariate model showed that time and
age significantly predicted a decrease in MMSE score
(Table 3). The interaction between time and age indi-
cates a decreasing rate of decline over time.
For the 323 participants who developed AD dur-
ing follow-up, 318 Katz ADL scores were available
at the moment of AD diagnosis, 109 at 3 years after
diagnosis, and 28 at 6 years after diagnosis.
Figure 2b presents the observed average Katz ADL
scores over time. The univariate analyses showed that
age, education, MMSE, and time significantly pre-
dicted the Katz ADL score. The multivariate model
showed that time significantly predicted an increase
in the Katz ADL score. The interaction between age
(measured at each assessment) and MMSE score, as
well as that between MMSE score and time after
being diagnosed, were significant. Higher education
predicted an increase in dependency (Table 3). Box 1
provides an overview of the regression formulas that
describe the course of MMSE and ADL.
DISCUSSION
In this long-term population-based prospective
study, we found that (1) the median AD dementia free
survival time was 3.5 years from the onset of MCI;
(2) after the onset of dementia, cognition declined at
a mean rate of 1.84 MMSE points per year; (3) Katz
ADL dependency score increased at a mean rate of
0.38 points per year; and (4) the above results yielded
the mathematical expressions presented in box 1 to
describe the natural decline of AD in relation to age,
gender, and education.
Our estimates (conversion rate: 7.3%, CI: 5.5–9.7%)
are within the confidence intervals of a pooled estimate
of the conversion of MCI to AD obtained by averaging
several population-based studies of MCI (conversion
rate 6.8, CI: 1.9–14.5) [18]. Our punctual estimate of
7.3% for MCI conversion to AD is slightly higher that
the pooled punctual estimate of 6.8% calculated by
Mitchell et al. [18] and this may be due to the fact that
our definition of MCI included cases with global cogni-
tive deterioration (OCIND) who progress faster to AD
(aMCI conversion rate was 6.7 and OCIND conver-
sion rate was 7.5). The cumulative conversion rate of
31% suggests that some of the MCI subjects improve
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Fig. 1. Course of observed MMSE over time. Each line represents an individual; time = 0 represents the moment when dementia is diagnosed
(using a 1.5 year time correction), time = −6 represents 6 years before the diagnosis of dementia.
Table 2
Hazard ratio (95% CI) of AD in the MCI cohort using a parametric survival model with Weibull distribution
Factors AD Hazard Ratio (95% CI) univariate analyses AD Hazard Ratio (95% CI) multivariate analysis
Gender (male) 0.38 (0.16 to 0.90)* 0.38 (0.16 to 0.90)*
Age at MCI diagnosis 1.06 (0.99 to 1.14)
Education 0.94 (0.84 to 1.05)
MMSE at MCI diagnosis 0.92 (0.80 to 1.07)
Katz at MCI diagnosis 1.17 (0.72 to 1.88)
∗p < 0.05.
and some die before developing dementia [19]. Our
decision to use parametric survival analysis requires
stricter distributional assumptions, though assuming a
specific baseline hazard shape allows the survival func-
tion to be used to simulate time to event data for health
economic modeling.
A population-based study including 95 incident
dementia participants [20, 21] found an average rate of
cognitive decline of 1.71 MMSE points per 6 months,
whereas we found a lower average rate of decline (1.84
/ 2 = 0.92 points per 6 months). The difference could
be explained by the inclusion of a higher proportion of
moderately severe dementia participants in the Kung-
sholmen Project, who decline less quickly due to the
floor effect of the MMSE. According to the multi-
variate model using average age, subjects decline by
1.2 MMSE points in the first 6 months after being
diagnosed.
Mendiondo et al. [22] and Mohs et al. [23] parame-
terized the annual rate of cognitive decline and found
a U-shaped pattern with low decline rates in mild and
severe dementia and a higher decline rate in between.
We explored this model, but the results were not
significant and could be attributed to the use of a
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Fig. 2. Course of average observed MMSE over time and the average Katz scores observed over time among incident dementia cases (time = 0
represents the moment dementia is diagnosed; a time correction of 1.5 years was applied; n = xx represent data points available).
Table 3
Regression parameter estimates (95% CI) of univariate and multivariate mixed effects regression model to predict MMSE (to reflect cognition)
and Katz score (to reflect ADL), n = 323
Cognition (MMSE) ADL (Katz score)
Factors Univariate Multivariate Univariate Multivariate
Intercept – 26.87 (24.45 to 29.29 – −0.82 (−2.30 to 0.65)
Time as years after
being diagnosed
with dementia
−1.84 (−2.10 to −1.57)* −3.26 (−4.56 to −1.97)** 0.38 (0.29 to 0.46)** 0.26 (0.08 to 0.44)**
Gender (male) −1.14 (−2.89 to 0.60) – 0.33 (−0.15 to 0.81) –
Age at each
assessment moment
normalized at 75
−0.41 (−0.57 to −0.26)* −0.35 (−0.53 to −0.16)** 0.15 (0.11 to 0.20)** 0.26 (0.16 to 0.36)**
Education −0.05 (−0.29 to 0.19) – 0.08 (0.02 to 0.14)* 0.06 (0.00 to 0.11)**
MMSE at each
assessment moment
– – −0.16 (−0.18 to −0.14)** 0.02 (−0.05 to 0.08)
Time squared (2nd
order polynomial)
– – – –
Interaction time*age – 0.10 (0.01 to 0.19)* – –
Interaction
MMSE*age
– – – −0.01 (−0.01 to −0.00)**
Interaction
MMSE*time
– – – −0.01 (−0.02 to −0.00)*
Variance random
intercept
– 2.00 – 0.71**
Variance random time
effect
– 1.86 – –
Covariance random
intercept and
random time effect
– 1.73* – –
∗p < 0.05, ∗∗p < 0.01.
population-based sample instead of a clinical sample,
as the latter probably includes persons with a poorer
prognosis because consulting a medical professional is
probably initiated by the person’s memory complaints.
Han et al. [24] reviewed studies largely based on clin-
ical samples of prevalent cases with an average of 2
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years of follow-up, and found a mean annual rate of
decline of 3.3 MMSE points per year. Our estimates are
at the lower bound of their confidence interval. Besides
the use of incident community participants, this differ-
ence could be explained by the long follow-up time,
in which some participants reach the floor level of the
MMSE.
Our model for dependency estimated that more
years of education increased dependency. This can be
explained by higher educated persons having a cog-
nitive reserve which delays receiving a diagnosis of
dementia [25]. By the time the diagnosis is established,
the disease is probably more severe than in less edu-
cated persons, which could mean that higher educated
persons have a poorer prognosis. Gender was not found
to be significant in the analyses on the demented sub-
jects, which might be explained by limited statistical
power, since the sample included about 17% males.
In both the MMSE and ADL models, the effect of age
indicates a more rapid decline among younger persons.
The interaction effects between time and age in the
MMSE model runs counter to the effect of time. This
suggests a decreasing rate of decline in the later stages
of the disease. However, it can also be explained by the
bottom level of the MMSE that might be less sensitive
in severely demented persons.
The strength of our study was the use of a 6-year
follow-up period and the prospective study design.
Nevertheless, the study was subject to several limita-
tions. The Kungsholmen project included persons aged
75 and older, which resulted in attrition due to death
and refusal. However, this reflects reality, since most
demented people are older than 75 [26], and the mixed
model with random effects and the survival analysis
take missing or censored data into account. Nonethe-
less, generalization to a younger population should be
done with caution, although our finding of a positive
relation between age and cognition was also found
in clinical samples with a younger age [27]. A sec-
ond limitation is that the Kungsholmen project started
in 1987, when the current cholinesterase inhibitors
and memantine treatments that affect cognitive decline
were not available. In addition, advances in diagnos-
tics, especially for MCI, might limit the generalization
of our findings to the current care standards. Thirdly,
the 3-year interval between our measurements may
have resulted in a biased estimate of AD dementia
free survival in MCI subjects, because a participant
may progress to dementia via MCI within an interval
without being assessed. Fourthly, the empirical models
were not adjusted for comorbidities, as this infor-
mation was not available to the researchers. Finally,
visual comparison between the observed and estimated
hazard rates from the survival analysis indicated a
difference that can be attributed to the use of 3-year
average intervals between assessments. This discrep-
ancy most likely also explains the difference between
the observed time until 75% AD free survival (3.2
years) and the estimated survival time derived from the
fitted survival model (4.6 years). Furthermore, the 1.5
year correction might limit the precision of the time-to
dementia conversion.
The empirical models in Box 1 could be used to
simulate the natural disease progression in a cohort
and compare this with a scenario where a hypothetical
future treatment is available. Such predictions can be
integrated with evidence on health care resource usage
and quality of life, and enable policy makers to address
questions about the potential of new diagnostic or treat-
ment interventions from a cost-effectiveness point of
view [28]. Such analyses could provide added value
to randomized controlled trials which are limited in
terms of follow-up time or the number of scenarios to
compare [3]. This should, however, be done with cau-
tion, for several reasons. The regression and survival
models have not been validated by external datasets,
or by predicting the progress of similar patients in
current clinical practice. The data available at follow-
up was limited, resulting in uncertain predictions. If
these results are to be integrated with those from other
sources, the populations must be similar. This might
represent a difficulty for the evaluation of diagnos-
tic and treatment scenarios, since their evidence is
often collected in clinical settings and differs from that
derived from a population-based study. This stresses
the importance of using sensitivity analysis in decision
models to address these issues. Finally, generalizabil-
ity to other countries is limited because differences in
life expectancy might lead to differences in average
disease progression rates or the effect of age.
Caution should be used when combining evidence
from sources that reflect different populations. Sam-
ples recruited within a clinical setting will most likely
show more progressive decline, on which age, gender,
and education might have different influences. Fur-
thermore, different criteria and subdivisions of MCI
have been proposed and modified over time, with
different characterizations of cognitive decline (e.g.,
aMCI specifically reflecting an AD cause and OCIND
including a broader range of potential causes [29]). In
addition, extrapolation of the results outside the 6-year
time frame should also be done with caution.
In conclusion, our results reflect the natural his-
tory of AD in the pre-dementia and dementia phases
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in terms of cognition and dependency. Since the
study was based on community incident cases of
MCI and AD dementia, its results can be applied
for effectiveness and cost-effectiveness evaluations of
interventions in early AD.
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